Mutation-Specific Zebrafish Models for Human AML Drug Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current models fail to accurately represent the diverse mutation profiles of acute myeloid leukemia (AML), hindering the development of personalized treatment strategies.
Innovation Solution
Development of genetically modified zebrafish models that stably express specific mutation combinations commonly found in human AML, such as FLT3ITD+IDH2R140Q or FLT3ITD+IDH2R172K, allowing for the study of AML initiation and progression and high-throughput drug screening.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy and allogeneic hematopoietic stem cell transplantation are used as standard treatment, then treatment coverage is comprehensive, but patient outcomes remain unsatisfactory due to the one-size-fits-all approach
Solution Approach 1:
The patent segments AML treatment by creating distinct zebrafish models for different mutation combinations (FLT3-ITD, IDH2-R140Q, IDH2-R172K, SRSF2-P95H, NRAS-G12D). Each model represents a specific molecular subtype, enabling targeted therapy development for each segment rather than a unified approach.
Solution Approach 2:
The patent changes the parameter of genetic composition in zebrafish models to match specific human AML mutation profiles. By introducing precise genetic modifications (e.g., FLT3-ITD with IDH2-R140Q), the models reflect the heterogeneity of AML, allowing therapy evaluation tailored to specific molecular parameters.
2Measurement precision
If existing AML models are used, then general AML characteristics can be studied, but specific mutation combinations and their unique leukemic phenotypes cannot be accurately represented
Solution Approach 1:
The patent applies local quality by introducing specific mutations at precise genomic loci in zebrafish. Each model carries defined mutation combinations (e.g., FLT3-ITD plus IDH2-R140Q) that replicate the local genetic alterations found in specific human AML cases, enabling accurate study of mutation-specific phenotypes.
Solution Approach 2:
The patent creates a universal platform using zebrafish that can model multiple AML mutation combinations within a single organism system. The same zebrafish platform serves multiple functions by accommodating different genetic modifications, allowing comprehensive study of various AML subtypes without requiring entirely separate model systems.
3Adaptability or versatility
If multiple AML models with different mutation combinations are developed, then personalized therapy screening capability is improved, but the complexity and resources required for model development and maintenance increase
Solution Approach 1:
The patent creates simplified copies of human AML genetic profiles in zebrafish. By replicating specific mutation combinations (e.g., FLT3-ITD+IDH2-R140Q) in a smaller, more manageable organism, the system enables high-throughput therapy screening without the complexity of using human cell lines or animal models.
Solution Approach 2:
The patent utilizes zebrafish, which are smaller, less expensive, and have shorter lifespans compared to mammalian models. This allows for more economical and rapid generation of multiple model lines with different mutation combinations, facilitating extensive therapy screening without prohibitive costs or time requirements.
Data Source
AI summary
Genetically modified zebrafish, in which mutation combinations frequently identified in human AML are stably expressed in the stem cell population of the fish, are provided. The combination of mutations result in morphologic, cytochemical and molecular changes of its blood cells that are remarkably similar to those in human AML. The zebrafish model provides a foundation for the study of AML initiation and progression and a high throughput in vivo drug screening platform to identify personalized therapies for AML based on specific mutation combinations. The method of drug screening includes contacting embryos or adult fish containing mutations as disclosed herein, with a test agent, at test concentrations and test intervals to determine the therapeutic effect if any, of the test agent.